# OnCo record elotuzumab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/elotuzumab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "elotuzumab" ;
  schema:name "Elotuzumab"@en ;
  schema:description "An immune-stimulating antibody for myeloma that works only in combination, adding benefit to lenalidomide or pomalidomide."@en ;
  schema:url <https://onco.cc/drugs/elotuzumab/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Elotuzumab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q3723645> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=elotuzumab> ;
  onco:status "approved" ;
  onco:tag "gap-fill" ;
  onco:modality "Anti-SLAMF7 monoclonal antibody" ;
  schema:alternateName "Empliciti" ;
  onco:approval "US 2015: Multiple myeloma after 1-3 prior therapies, with lenalidomide-dexamethasone", "US 2018: With pomalidomide-dexamethasone after ≥2 therapies" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:companies <https://onco.cc/companies/bms/> ;
  onco:terms <https://onco.cc/terms/adcc/> ;
  onco:trials <https://onco.cc/trials/nct05730036/>, <https://onco.cc/trials/nct06152575/>, <https://onco.cc/trials/nct06158841/>, <https://onco.cc/trials/nct06208150/>, <https://onco.cc/trials/nct03989414/> .